tbuckley/cabot-search huggingface dataset:
Treatment patterns and clinical outcomes of patients with early triple negative breast cancer at a tertiary medical center.
Authors: Julia C. Tchou, Laura Burkbauer, Macy Goldbach, Angela Malinovitch, Luke Keele
Journal: Journal of Clinical Oncology (2020)

e12624 Background: The clinical benefit of neoadjuvant chemotherapy in patients with early triple negative breast cancer (eTNBC), especially those with clinical stage I (cStage I) disease, remains unclear. This study aims to examine the treatment pattern and outcomes of patients with eTNBC treated at a tertiary medical center. Methods: After receiving IRB approval, clinical characteristics, treatment patterns and invasive disease-free survival (iDFS) outcomes of patients with eTNBC treated in 2009-2019 were compared between those who received adjuvant chemotherapy (AC) vs. neoadjuvant chemotherapy (NAC). Inverse probability weighting (IPW) statistical methods were used to adjust for subgroup imbalances including age, race, clinical T and N stage. Results: Study cohort (n=919) was 70% white and 25% black. Median follow-up for AC and NAC was 49+/-26 and 28+/-19 months respectively. The majority, 56% (400/717), in AC had cStage I disease while only 8% (16/202) in NAC had cStage I disease. Other clinical characteristics were summarized in Table. The most common chemotherapy regimen used in AC and NAC groups was AC-T: 58% and 79%; followed by TC: 32% and 4%; and carboplatin: 2% and 5% respectively. pCR was noted in 83 patients (41%). Multivariate analyses using IPW showed that AC conferred an improved iDFS with a gain of 18 months in those with &lt;=cStage IIA compared to NAC with pCR (Table). Conclusions: Despite limitations including our small sample size and retrospective study design, our results showed that NAC appeared to only benefit eTNBC patients with higher disease burden (&gt;=cStageIIB). Future work to elucidate the clinical benefits of emerging novel NAC strategies in eTNBC will be of interest. [Table: see text]
新诊断糖尿病患者的临床处理
Authors: 傅汉菁
Journal: BMJ (2007)

随着我国人民生活水平的迅速提高,生活模式西方化以及社会的老龄化,糖尿病的患病率在逐年增加,其中新诊断的糖尿病患者日益增多.在门诊就诊的糖尿病患者中有不少是新诊断的糖尿病患者,他们有的是因为其他疾病化验尿常规发现尿糖阳性进一步检查发现糖尿病;有的因为手术前查体常规化验肝肾功能和血糖,发现空腹血糖升高;还有的是在健康体检时发现空腹血糖升高.面对这些新诊断的糖尿病患者,我们在诊断、化验、治疗方面应该做些什么工作呢?
Effectiveness of clinician-involving predischarge and follow-up health education for patients with esophageal cancer
Authors: Chunmei You, Wenze Tian, Dafu Xu, Zhongwu Hu, Yongjian Sun, Zhenbing You
Journal: BMJ (2019)

One hundred and eighty three patients with esophageal cancer admitted from September 2015 to September 2016 were randomly divided into two groups: 91 patients received clinician-involving pre-discharge and postoperative follow-up health education (study group) and 92 patients received traditional health education (control group). The quality of life and the compliance rate of comprehensive treatment within 3 months after discharge were evaluated and compared between two groups. The overall scores of quality of life in study group was significantly better than those of the control group (P<0.05), and the compliance rate of comprehensive treatment after discharge in study group was significantly higher than that of control group [82.4%(75/91) vs. 67.4%(62/92), χ2=5.49, P=0.02]. It is suggested that clinician participating in the pre-discharge and follow-up health education can improve the quality of life of patients, and improve the compliance of comprehensive treatment after discharge.


Key words: 
Esophageal neoplasms; Quality of life; Patient education
TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).
Authors: Nadine M. Tung, Mark E. Robson, Steffen Ventz, Cesar Augusto Santa-Maria, Paul Kelly Marcom, Rita Nanda, Payal D Shah, Tarah Jean Ballinger, Eddy Shih-Hsin Yang, Michelle E. Melisko, Adam Brufsky, Shaveta Vinayak, Michelle Demeo, Colby Jenkins, Susan M. Domchek, Gerburg M. Wulf, Ian E. Krop, Antonio C. Wolff, Eric P. Winer, Judy Ellen Garber
Journal: Journal of Clinical Oncology (2020)

1002 Background: Olaparib, a PARP inhibitor, is approved for HER2-negative MBC in g BRCA1/2 mutation carriers. Olaparib Expanded, an investigator-initiated study, assessed the response to olaparib in MBC patients with sBRCA1/2 mutations or g/s mutations in DDR-pathway genes other than BRCA1/2. Methods: Eligibility included: MBC with measurable disease; progression on &lt; 2 metastatic chemotherapy regimens. Prior PARP inhibitor or progression on platinum was not allowed. Cohort 1 included patients with germline mutations in non- BRCA1/2 DDR-pathway genes. In Cohort 2 were those with somatic mutations in these genes or BRCA1/2; germline testing was required only to exclude a gBRCA mutation if a s BRCA mutation was present. Patients received olaparib 300 mg bid until progression or unacceptable toxicity. For each cohort, a single-arm Simon two-stage design was used with 13 then 14 patients in the 1 st and 2 nd stages, respectively. The null hypothesis within each cohort [≤ 5% objective response rate (ORR)] would be rejected if &gt; 4 responses were seen at the end of stage 2. Secondary endpoints include clinical benefit rate, progression-free survival, and duration of response. Results: 54 patients enrolled from March 2018 to Jan 2020; 1 ineligible s BRCA2 was excluded. Median age was 59 yrs (range: 30-87). 40 patients had ER+ HER2-, 3 HER2+, and 10 TNBC. 87% had a mutation in PALB2, s BRCA1/2, ATM or CHEK2. ORR was 29.6% (8/27, 90%-CI: 15.6%-47.1%) in Cohort 1 and 38.5% (10/26, 90%-CI: 22.5%-56.4%) in Cohort 2. Responses were gene specific (Table): g PALB2 and s BRCA mutations predicted response; no responses were seen with only a CHEK2 or ATM mutation. To date, responses as long as 16.4 months have been observed. Responses were seen in all subtypes: 5/10 TNBC, 1/3 HER2+, 12/40 ER+ HER2-. 11 responses occurred after prior CDK4/6 inhibitor. In June 2020, final data for confirmed ORR and secondary endpoints will be reported. Conclusion: In this proof-of-principle study, single-agent olaparib successfully met its primary endpoint in both cohorts. Activity was seen largely in patients with MBC and s BRCA1/2 or g PALB2 mutations but not with ATM or CHEK2 mutations. Clinical trial information: NCT03344965 . [Table: see text]
Clinical analysis for relationship between fasting blood glucose level and cardiovascular risk factors in the elderly
Authors: 王红, 李明升, 邓丽丽, 王继红, 左庆瑶, 彭璐, 郭朝晖
Journal: BMJ (2004)

目的 探讨老年人不同空腹血糖水平与心血管危险因素的关系.方法选择积水潭医院60岁以上的职工378例,检测体重指数、血压、空腹血糖、血脂、血尿酸及纤维蛋白原,依据美国糖尿病学会空腹血糖诊断标准分为3组:糖尿病组、空腹血糖异常组和正常空腹血糖组,对3组人群进行对比分析. 结果糖尿病组40例,空腹血糖异常组54例,空腹血糖正常组284例.糖尿病组体重指数、舒张压、总胆固醇、甘油三酯、纤维蛋白原明显高于空腹血糖正常组(P<0.05),高密度脂蛋白胆固醇显著低于空腹血糖正常组(P<0.05);空腹血糖异常组体重指数明显高于空腹血糖正常组(P<0.05);糖尿病组舒张压、总胆固醇、甘油三酯、纤维蛋白原明显高于空腹血糖异常组(P<0.05),高密度脂蛋白胆固醇明显低于空腹血糖异常组(P<0.05).结论依据美国糖尿病学会标准诊断的老年糖尿病病前状态(空腹血糖异常阶段)有低估心血管危险因素的倾向,需要寻找一种既经济又有效的筛查方法确定糖尿病病前状态,发现并控制心血管危险因素,降低心血管疾病的患病率。
Disparities in receipt of and time to adjuvant therapy after lumpectomy.
Authors: Irene Dankwa-Mullan, M. Christopher Roebuck, Joseph Tkacz, Oluwadamilola Motunrayo Fayanju, Yi Ren, Gretchen Purcell Jackson, Yull Edwin Arriaga
Journal: Journal of Clinical Oncology (2020)

534 Background: Adjuvant treatment after breast conserving surgery (BCS) has been shown to improve outcomes, but the degree of uptake varies considerably. We sought to examine factors associated with post-BCS receipt of and time to treatment (TTT) for adjuvant radiation therapy (ART), cytotoxic chemotherapy (ACT) and endocrine therapy (AET) among women with breast cancer. Methods: IBM MarketScan claims data were used to select women diagnosed with non-metastatic invasive breast cancer from 01/01/2012 to 03/31/2018, who received primary BCS without any neoadjuvant therapy, and who had continuous insurance eligibility 60 days post-BCS. Logistic and quantile regressions were used to identify factors associated with receipt of adjuvant therapy (ART, ACT, AET) and median TTT in days for ART (rTTT), ACT (cTTT), and AET (eTTT), respectively, after adjustment for covariates including age, year, region, insurance plan type, comorbidities, and a vector of ZIP3-level measures (e.g., community race/ethnicity-density, education level) from the 2019 Area Health Resource Files. Results: 36,270 patients were identified: 11,996 (33%) received ART only, 4,837 (13%) received ACT only, 3,458 (10 %) received AET only, 5,752 (16%) received both ART and AET, and 9,909 (27%) received no adjuvant therapy within 6 months of BCS. (318) 1% of patients received combinations of either ART, AET or ACT. Relative to having no adjuvant therapy, patients &gt; 80 years were significantly less likely to receive ART only (relative risk ratio [RRR] 0.65), ACT only (RRR 0.05), or combination ART/AET (RRR 0.66) but more likely to receive AET alone (RRR 3.61) (all p &lt; .001). Patients from communities with high proportions of Black (RRR 0.14), Asian (RRR 0.13), or Hispanic (RRR 0.45) residents were significantly less likely to receive combination ART and AET (all p &lt; .001). Having HIV/AIDS (+11 days; p = .01) and residing in highly concentrated Black (+8.5 days; p = .01) and Asian (+12.2 days; p = .04) communities were associated with longer rTTT. Longer cTTT was associated with having comorbidities of cerebrovascular disease (+6.0 days; p &lt; .001), moderate to severe liver disease (+12.3 days; p &lt; .001) and residing in high-density Asian communities (+18.0 days; p &lt; .001). Shorter eTTT (-11.4 days; p = .06) and cTTT (-14.8 days; p &lt; .001) was observed in patients with comorbidities of dementia. Conclusions: Results from this cohort of privately insured patients demonstrate disparities in receipt of post-BCS adjuvant radiation and systemic therapy along multiple demographic dimensions and expose opportunities to promote timely receipt of care.
Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).
Authors: Arvind Dasari, Daneng Li, Max W. Sung, Christopher Tucci, John S. Kauh, Marek K. Kania, Andrew Scott Paulson
Journal: Journal of Clinical Oncology (2020)

4610 Background: Surufatinib (S) is a targeted inhibitor of tyrosine kinases VEGFR1, 2, &amp; 3, FGFR1, and CSF-1R. Safety and efficacy of S has previously been studied in China in early phase development, and in 2 randomized phase 3 placebo controlled trials (NCT02588170 &amp; NCT02589821). These trials enrolled pts with NETs of extrapancreatic (epNET) and pancreatic (panNET) origin, respectively. Both trials are completed, stopping at their pre-planned interim analysis after meeting the primary endpoint of improved PFS. S demonstrated significant efficacy in pts with advanced epNETs, achieving a median Progression Free Survival [mPFS] of 9.2 v 3.8 months when compared to placebo. The mPFS achieved in pts with advanced panNETs is currently pending future disclosure at an upcoming scientific conference. Methods: A dose escalation (ESC)/expansion (EXP) study was conducted to evaluate and confirm the effects of S in US pts. Dose ESC was completed and the maximum tolerated dose and recommend phase 2 dose was determined to be 300mg QD; the same as previous trials. The primary objective of EXP was to evaluate anticancer activity in pts with select indications including panNETs and epNETs. Results: As of 21-Jan-20, 32 pts with heavily pre-treated progressive NETs (median prior lines of treatment [Tx]: 3; range 1-8) were enrolled. The 32 pts included 16 pts with panNET and 16 with epNET. All previously received everolimus and/or sunitinib. The median duration of Tx at the time of the data cut-off was 19 wks for all pts; 30.9 wks for panNET and 11 for epNET. 19 pts remain on active Tx (13 epNET and 6 panNET pts), 9 pts discontinued due to progression of disease, 2 withdrew consent and 2 discontinued due to adverse event (AE) (grade 3 tricuspid valve insufficiency, and grade 3 GI bleed). An objective response rate of 9.4% was observed. 3 panNET pts achieved a confirmed partial response (PR) and 1 had an unconfirmed PR per RECIST 1.1; no epNET pts achieved a PR. The safety profile of S remains consistent with previously completed trials. 27 pts (84.4%) had reported at least one adverse event (AE), and 16 pts (50%) reported ≥ grade 3 AE’s. The most common AE’s reported were: hypertension, fatigue, diarrhea, proteinuria and nausea. Pharmacokinetics (PK) analyses has shown similar exposure in panNET and epNET pts as was observed in ESC, and pts from the collective pool of pts. Conclusions: S has demonstrated promising antitumor activity in US pts with progressive NETs with a manageable safety profile. Additionally, PK and dose exposure data is consistent with trial results from large randomized phase 3 trials. Clinical trial information: NCT02549937 .
Is autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) patients achieving only a PET/CT positive partial remission (PR) appropriate in the CAR-T cell era?
Authors: Nirav Niranjan Shah, Kwang Woo Ahn, Carlos Litovich, Timothy Fenske, Mehdi Hamadani
Journal: Journal of Clinical Oncology (2020)

8000 Background: In relapsed, chemosensitive DLBCL patients (pts), autoHCT consolidation is a standard therapy option. With the approval of anti-CD19 CAR T-cells in 2017, relapsed DLBCL pts with residual PET/CT avid disease after salvage therapies are increasingly being offered CAR T-cells in lieu of autoHCT. According to Center for International Blood and Marrow Transplant Research (CIBMTR) data in 2018, the number of autoHCT for DLBCL in the U.S. decreased by ~45% from prior years, likely due to application of CAR T-cells for both chemorefractory DLBCL and chemosensitive DLBCL pts not achieving a complete remission. Using the CIBMTR database, we report outcomes of autoHCT in relapsed chemosensitive DLBCL pts achieving only a PET/CT+ PR prior to HCT. Methods: 249 relapsed DLBCL pts undergoing an autoHCT from 2003-13 with a PET/CT+ PR prior to transplant were identified. The study cohort was divided into two groups: (a) early chemo-immunotherapy failure (ECF) defined as pts with primary refractory disease (PRefD) or relapse within 12 months of diagnosis, (b) late chemoimmunotherapy failure (LCF) defined as pts relapsing ≥12 months. Primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS) and relapse. Results: 182 pts had ECF and 67 pts had LCF. The median age of ECF pts was 57 years versus (vs) 63 years for LCF (p &lt; 0.01). ECF pts more frequently had stage III-IV at diagnosis (74% vs 54%, p = &lt; 0.01). 79% of ECF pts had PRefD. The most common conditioning regimen was BEAM in both cohorts. The adjusted 5-year probabilities for PFS and OS (ECF vs LCF) was not different between the 2 cohorts: 41% vs 41% (p = 0.93) and 51% vs 63% (p = 0.09), respectively. Cumulative incidence of relapse at 5 years in similar order was 48% vs 57%, p = 0.27. On multivariate analysis compared to the LCF, pts with ECF had an increased risk of death (HR = 1.61, 95%CI 1.05-2.46, p = 0.03) but no increased risk in PFS or relapse. Conclusions: Using the CIBMTR registry, we report outcomes of relapsed DLBCL pts in a PR with residual PET/CT avid disease at time of autoHCT. While OS favored LCF pts, the adjusted 5-year PFS (41%) was comparable in both cohorts. This 5 year PFS is comparable to results reported in historical trials of auto-HCT for DLBCL. With no randomized data demonstrating superiority of CAR T-cell therapy in chemosensitive PR patients, these findings strongly support that autoHCT should remain the current standard of care for this patient population.
Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib.
Authors: Ian Flinn, Mazyar Shadman, Benjamin Bruce Freeman, Dih-Yih Chen, Xiaoping Zhang, Aileen Cohen, Sunhee K. Ro, Jane Huang, Jeff P. Sharman
Journal: Journal of Clinical Oncology (2020)

TPS8066 Background: Ibrutinib (ibr), a Bruton tyrosine kinase inhibitor (BTKi), was shown to improve patient outcomes in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); however, adverse events (AEs) were the most common reason for discontinuing ibr (50% and 63% of discontinuations in relapse/refractory (R/R) and frontline patients, respectively; Haematologica. 2018:103:874). Zanubrutinib, an approved BTKi for mantle cell lymphoma, was specifically engineered to optimize selectivity. Pooled clinical data from 6 zanubrutinib monotherapy trials in B-cell malignancies (N=682 patients; R/R CLL/SLL [n=91]) suggested that zanubrutinib monotherapy was well tolerated and demonstrated a low rate of treatment discontinuation from AEs (9%; Tam, EHA 2019). Presented here is a trial-in-progress that will evaluate whether zanubrutinib monotherapy may serve as a therapeutic option for patients with CLL/SLL who have become ibr intolerant. Methods: The ongoing phase II, multicenter, US, single-arm, open-label study (NCT04116437, BGB-3111-215) will evaluate zanubrutinib monotherapy (160mg twice daily) as a treatment option for patients with CLL/SLL intolerant to prior ibr treatment. Approximately 60 patients will be enrolled from ~30 community medical centers. Key inclusion criteria include CLL/SLL requiring treatment per International Workshop on CLL criteria ( Blood. 2018;131:2745) before ibr therapy, intolerance to ibr (defined as an unacceptable AE for which, per investigator’s opinion, ibr treatment should be discontinued despite optimal supportive therapy), resolution of ibr-related AEs to grade ≤1 or baseline, and an ECOG PS 0-2. Key exclusion criteria include having an intervening cancer therapy between ibr and zanubrutinib, a documented disease progression during ibr treatment up to the time of enrollment, and a history of central nervous system (CNS) hemorrhage. The primary endpoint is frequency and severity of protocol-specified treatment-emergent AEs (diarrhea, myalgia, muscle spasm, arthralgia, hypertension, fatigue, rash, atrial fibrillation, and hemorrhage excluding CNS hemorrhage). The secondary endpoints include overall response rate, progression-free survival, and patient-reported outcomes. An exploratory endpoint was added to evaluate clinical effects (physical activity, treatment-related symptoms, and quality of life) using a smartphone app. Recruitment is ongoing. Clinical trial information: NCT04116437 .
Correlates of treatment compliance in infertile patients with polycystic ovary syndrome
Authors: Sai-jiao Li, Jing Yang, Ai-yan He, Tai-lang Yin, Wang-ming Xu, Yu-jie Zou
Journal: BMJ (2011)

Objective To investigate factors that correlated to compliance of treatment in infertile patients with polycystic ovary syndrome (PCOS) to provide basis for clinical treatment, specialist consultation and health education. Methods Compliance was assessed by a questionnaire designed by reference to Morisky-Green test and therapeutic principles for PCOS. Interviews were performed in 128 infertile patients with PCOS in Renmin Hospital of Wuhan University, Wuhan, Hubei in China during March 2009 to September 2010. Data were analyzed with logistic regression. Results Logistic regression analysis revealed that a total of 41 (34.2% ) of 120 participants investigated showed good compliance. Factors that might significantly (P ＜ 0.05 ) correlate compliance of treatment included body mass index (BMI) of the patients ( OR = 2.426, 95% CI = 1.428 - 4.121 ), length of their marriage ( OR = 0.398, 95% CI =0.225 - 0.704) and their concerns for adverse drug reactions ( OR= 0.216, 95% CI = 0.067 - 0.694).Conclusions Patients with obesity, shorter length of marriage and concerns for adverse drug reactions show lower compliance. Publicity and intervention to those patients should be strengthened in clinics to improve their treatment compliance in patients with PCOS.

Key words: 
Polycystic ovary syndrome;  Infertility, female;  Patient compliance;  Regression analysis
Incidence of tuberculosis at a university from 2007 to 2010
Authors: Hanjuan Li, Chunmei Liu, Baihua Xu, Feiyang Hu
Journal: BMJ (2014)

The statistics of purified protein derivative (PPD) test and chest radiograph of freshmen at a university from 2007 to 2010 were collected and examined. The result showed 25 tuberculosis cases (a prevalence rate of 0.18%) and 1 790 cases (13.40%) with strong positive PPD. After giving informed consents, the students with strong positive result and no abnormality on chest radiograph were divided into two groups. The treatment group (n=814) received precautionary anti-tuberculosis treatment while the non-treatment group (n=976) had no treatment. And 34 tuberculosis cases were found during four years in school (0.25%). Except for freshmen in 2008, the prevalence rate of the strong positive PPD groups much higher than that of the positive and negative groups and the difference had statistic significance between the groups (χ2=23.20, 10.58, 18.80, P<0.05). Therefore PPD test and chest radiograph are two main methods for an early diagnosis of tuberculosis among freshmen. Adopting precautionary anti-tuberculosis treatment for students with strong positive PPD and regular physical examinations are effective measures for tuberculosis control at universities.


Key words: 
Tuberculosis; Tuberculosis precaution
SRC-homology 2 domain-containing phosphatase 2 (SHP2) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD).
Authors: Rafael Rosell, Masaoki Ito, Jordi Codony-Servat, Ana Giménez-Capitán, Mireia Serra-Mitjans, Francisco Pérez-Ochoa, David Llige, Imane Chaib, Ramón Rami-Porta, Carme Obiols, Sergi Call, José Belda-Sanchis, Xavier Tarroch-Sarasa, Niki Karachaliou, Miguel Angel Molina Vila, Morihito Okada
Journal: Journal of Clinical Oncology (2020)

9540 Background: Epidermal growth factor (EGFR)-mutant lung adenocarcinomas (LUADs) display impaired phosphorylation of extracellular signal-regulated kinase (ERK) and SRC-homology 2 domain-containing phosphatase 2 (SHP2) in comparison with EGFR wild-type LUADs. However, the function of SHP2 in early EGFR-mutant LUADs and EGFR wild-type LUADs has not been reported. We posit that SHP2 mRNA expression could be a predictive marker in resected EGFR-mutant LUADs versus EGFR wild-type patients (pts). Methods: We examined 267 resected LUADs from Japan and Spain. mRNA expression levels of AXL, MET, CDCP1, STAT3, YAP1 and SHP2 were analyzed by quantitative reverse transcriptase polymerase chain reaction (PCR). EGFR mutant cell lines were investigated for their activity of SHP2. Results: Among the 267 enrolled pts, 100 (37.3%) were EGFR-mutant LUADs. Five-year recurrence-free survival (RFS) and overall survival (OS) were lower for EGFR-mutant LUADs with high SHP2 mRNA levels (hazard ratio = 1.83 and 2.28, respectively. p = 0.03 and p = 0.04). However, SHP2 was not associated with RFS nor OS in the 167 wild-type EGFR LUADs. In EGFR-mutant cells, RMC-4550 (SHP2 inhibitor) plus erlotinib showed synergism via inhibition of AKT (S473) and ERK1/2 (T202/Y204). While erlotinib translocates SHP2 (Y542) into the nucleus, either RMC-4550 alone, or in combination with erlotinib, relocalizes SHP2 into the cytoplasm membrane, limiting AKT and ERK activation. Conclusions: High SHP2 mRNA is related to shorter RFS and OS in EGFR-mutant LUADs, but not in EGFR wild-type LUADs. The findings indicate that the addition of SHP2 inhibitors could improve adjuvant therapy in EGFR-mutant LUADs.
Fahr病二例并文献复习
Authors: 王其军, 贾振丽, 刘红光, 马民, 张亮
Journal: BMJ (2009)

例1患者女,44岁,15年前因头部不适,有僵硬感,逐渐向左肩、背部蔓延,伴左侧肢体活动不便2年首次就诊.否认遗传病史及类似家族史.CT示颅内广泛钙化灶,右额叶片状低密度区,局部点状钙化(图1).7年前出现行走困难,呈小碎步态,左上下肢屈伸受限,出现不自主哭笑,头颅CT示原脑内钙化灶增大,右额叶片状低密度区,右侧脑室额角受压变形(图2)。